Annual Accounts Receivable
$297.24 M
+$214.87 M+260.84%
December 31, 2023
Summary
- As of February 7, 2025, NVAX annual accounts receivable is $297.24 million, with the most recent change of +$214.87 million (+260.84%) on December 31, 2023.
- During the last 3 years, NVAX annual accounts receivable has risen by +$35.23 million (+13.45%).
- NVAX annual accounts receivable is now -34.67% below its all-time high of $454.99 million, reached on December 31, 2021.
Performance
NVAX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$94.96 M
+$62.86 M+195.79%
September 30, 2024
Summary
- As of February 7, 2025, NVAX quarterly accounts receivable is $94.96 million, with the most recent change of +$62.86 million (+195.79%) on September 30, 2024.
- Over the past year, NVAX quarterly accounts receivable has dropped by -$28.70 million (-23.21%).
- NVAX quarterly accounts receivable is now -80.14% below its all-time high of $478.16 million, reached on March 31, 2022.
Performance
NVAX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
NVAX Accounts Receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +260.8% | -23.2% |
3 y3 years | +13.4% | -79.1% |
5 y5 years | +100.0% | +100.0% |
NVAX Accounts Receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -34.7% | +260.8% | -80.1% | +344.2% |
5 y | 5-year | -34.7% | +3863.2% | -80.1% | -100.0% |
alltime | all time | -34.7% | -100.0% | -80.1% | -100.0% |
Novavax Accounts Receivable History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $94.96 M(+195.8%) |
Jun 2024 | - | $32.10 M(+50.2%) |
Mar 2024 | - | $21.38 M(-92.8%) |
Dec 2023 | $297.24 M(+260.8%) | $297.24 M(+140.4%) |
Sep 2023 | - | $123.66 M(-68.7%) |
Jun 2023 | - | $394.89 M(+249.9%) |
Mar 2023 | - | $112.85 M(+37.0%) |
Dec 2022 | $82.38 M(-81.9%) | $82.38 M(-26.2%) |
Sep 2022 | - | $111.64 M(-42.6%) |
Jun 2022 | - | $194.53 M(-59.3%) |
Mar 2022 | - | $478.16 M(+5.1%) |
Dec 2021 | $454.99 M(+73.7%) | $454.99 M(+504.4%) |
Sep 2021 | - | $75.28 M(+50.6%) |
Jun 2021 | - | $49.99 M(-12.1%) |
Mar 2021 | - | $56.90 M(-78.3%) |
Dec 2020 | $262.01 M(+3393.5%) | $262.01 M(+2020.7%) |
Sep 2020 | - | $12.36 M(>+9900.0%) |
Jun 2020 | - | $0.00(0.0%) |
Mar 2020 | - | $0.00(-100.0%) |
Dec 2019 | $7.50 M(>+9900.0%) | $7.50 M(>+9900.0%) |
Dec 2018 | $0.00(-100.0%) | $0.00(-100.0%) |
Sep 2016 | - | $591.00 K(+62.8%) |
Jun 2016 | - | $363.00 K(-10.6%) |
Mar 2016 | - | $406.00 K(-82.5%) |
Dec 2015 | $2.32 M(-69.1%) | $2.32 M(+5.6%) |
Sep 2015 | - | $2.20 M(-6.2%) |
Jun 2015 | - | $2.34 M(-64.9%) |
Mar 2015 | - | $6.67 M(-11.1%) |
Dec 2014 | $7.51 M(+293.0%) | $7.51 M(+162.7%) |
Sep 2014 | - | $2.86 M(-23.1%) |
Jun 2014 | - | $3.72 M(-16.7%) |
Mar 2014 | - | $4.47 M(+133.7%) |
Dec 2013 | $1.91 M(+89.0%) | $1.91 M(0.0%) |
Sep 2013 | - | $1.91 M(+110.7%) |
Jun 2013 | - | $907.00 K(-65.1%) |
Mar 2013 | - | $2.60 M(+157.4%) |
Dec 2012 | $1.01 M | $1.01 M(-59.1%) |
Sep 2012 | - | $2.47 M(+64.8%) |
Jun 2012 | - | $1.50 M(-13.2%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2012 | - | $1.73 M(-12.2%) |
Dec 2011 | $1.97 M(+3538.9%) | $1.97 M(>+9900.0%) |
Sep 2011 | - | $17.00 K(-99.1%) |
Jun 2011 | - | $1.83 M(-27.2%) |
Mar 2011 | - | $2.52 M(+4561.1%) |
Dec 2010 | $54.00 K(-79.1%) | $54.00 K(-91.0%) |
Sep 2010 | - | $599.00 K(+68.3%) |
Jun 2010 | - | $356.00 K(+54.1%) |
Mar 2010 | - | $231.00 K(-10.5%) |
Dec 2009 | $258.00 K(-79.7%) | $258.00 K(-21.8%) |
Sep 2008 | - | $330.00 K(+0.9%) |
Jun 2008 | - | $327.00 K(-49.5%) |
Mar 2008 | - | $647.00 K(-59.6%) |
Sep 2007 | - | $1.60 M(+103.4%) |
Jun 2007 | - | $787.00 K(-13.1%) |
Mar 2007 | - | $906.00 K(-28.9%) |
Dec 2006 | $1.27 M(-64.3%) | $1.27 M(-59.2%) |
Sep 2006 | - | $3.13 M(-18.3%) |
Jun 2006 | - | $3.83 M(+6.2%) |
Mar 2006 | - | $3.60 M(+0.8%) |
Dec 2005 | $3.57 M(+331.8%) | $3.57 M(+211.3%) |
Sep 2005 | - | $1.15 M(+1.2%) |
Jun 2005 | - | $1.13 M(+81.0%) |
Mar 2005 | - | $626.00 K(-24.3%) |
Dec 2004 | $827.00 K(-57.8%) | $827.00 K(-53.5%) |
Sep 2004 | - | $1.78 M(-46.0%) |
Jun 2004 | - | $3.30 M(+42.3%) |
Mar 2004 | - | $2.32 M(+18.3%) |
Dec 2003 | $1.96 M(+4.1%) | $1.96 M(-31.5%) |
Sep 2003 | - | $2.86 M(+52.8%) |
Jun 2003 | - | $1.87 M(+47.3%) |
Mar 2003 | - | $1.27 M(-32.5%) |
Dec 2002 | $1.88 M(-51.5%) | $1.88 M(+24.3%) |
Sep 2002 | - | $1.51 M(-53.7%) |
Jun 2002 | - | $3.27 M(-16.1%) |
Mar 2002 | - | $3.90 M(+0.6%) |
Dec 2001 | $3.88 M | $3.88 M(+28.8%) |
Sep 2001 | - | $3.01 M(+20.7%) |
Jun 2001 | - | $2.50 M(+44.6%) |
Mar 2001 | - | $1.73 M |
FAQ
- What is Novavax annual accounts receivable?
- What is the all time high annual accounts receivable for Novavax?
- What is Novavax annual accounts receivable year-on-year change?
- What is Novavax quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Novavax?
- What is Novavax quarterly accounts receivable year-on-year change?
What is Novavax annual accounts receivable?
The current annual accounts receivable of NVAX is $297.24 M
What is the all time high annual accounts receivable for Novavax?
Novavax all-time high annual accounts receivable is $454.99 M
What is Novavax annual accounts receivable year-on-year change?
Over the past year, NVAX annual accounts receivable has changed by +$214.87 M (+260.84%)
What is Novavax quarterly accounts receivable?
The current quarterly accounts receivable of NVAX is $94.96 M
What is the all time high quarterly accounts receivable for Novavax?
Novavax all-time high quarterly accounts receivable is $478.16 M
What is Novavax quarterly accounts receivable year-on-year change?
Over the past year, NVAX quarterly accounts receivable has changed by -$28.70 M (-23.21%)